XiFin Inc. Helps Laboratory Clients Increase Their Valuations in M&A Transactions

XiFin Inc., the leading provider of revenue cycle management for diagnostic service providers, today announced the release of a white paper outlining how laboratory valuations can be positively impacted by the appropriate use of state of the art Revenue Cycle Management technologies.

The white paper, edited and hosted by Robert Michel, Editor-In-Chief of The Dark Report and President of The Dark Intelligence Group, Inc, details how three laboratories, US Labs, West cliff Medical Laboratories, and Piedmont Medical Laboratories used XiFin’s Software as a Service (SaaS) based Revenue Cycle Management to improve top line performance, while ensuring the revenue cycle process was optimized for productivity and regulatory compliance.

“Revenue Cycle Management (RCM) is a cornerstone of the cash flow and profitability generated by every clinical laboratory and outreach testing programs in this country,” observed Michel. “Yet there is little information available to laboratory executives, clinical lab managers, and pathologists about how to assess their laboratory’s effectiveness at RCM. This white paper fills that knowledge vacuum.

“The three laboratory case studies presented in the white paper on Revenue Cycle Management in clinical laboratories help any lab manager understand the practical ways that RCM can help every laboratory,” added Michel. “Another noteworthy aspect about this white paper is that it is available for a free download, 24/7 at the web site www.darkdaily.com. We are using Web 2.0 technologies to make this white paper on RCM available to the entire laboratory industry.”

“Our ability to recognize net revenue and maximize collections not only increased PML’s valuation, but played a key role in our ability to attract an M&A suitor, get the best price and quickly navigate the process” said Joe Skrisson, CEO of Piedmont Medical Laboratories.

“Maximizing laboratory reimbursement has always been the untapped reserve that can lead to increased valuation”, said Lâle White, XiFin’s CEO and Executive Chairman. “Laboratory valuation is all about top line revenue, profitability, and minimizing risk. All of these elements can be positively impacted by state of the art Revenue Cycle Management”

The white paper, A CEO’s Guide to Increasing Laboratory Valuation, can be downloaded from the Dark Daily website.

Click Here To access a “CEO’s Guide to Increasing Laboratory Valuation: Effective Revenue Cycle and Compliance Management are Critical Success Factors.”

For additional information, Contact: Bill Taylor (858) 436-2995

About XiFin

XiFin is an innovative software and services company dedicated to optimizing the economics of healthcare. The company’s cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making. To learn more, visit www.xifin.com, or follow XiFin on Twitter at www.twitter.com/#!/XiFin.